Egbring R, Kröniger A, Seitz R
Department of Hematology/Oncology, Philipps-University Hospitals, Marburg, Germany.
Semin Thromb Hemost. 1996;22(5):419-25. doi: 10.1055/s-2007-999041.
Congenital factor XIII deficiency is a rare disease, but has provided valuable information on the physiological role of factor XIII and the benefit of factor XIII replacement therapy. It could be shown that not only homozygous patients but also heterozygotes are at risk for bleeding complications. Acquired factor XIII deficiency, however, is much more common, and preliminary studies suggest a lack of factor XIII to be an important feature of various diseases. In acute states and severe hemorrhages, replacement therapy with factor XIII concentrates is recommended. Recent progress in assay methods and future clinical studies should help to evaluate the therapeutic potential of factor XIII.
先天性因子 XIII 缺乏症是一种罕见疾病,但它为因子 XIII 的生理作用以及因子 XIII 替代疗法的益处提供了有价值的信息。可以证明,不仅纯合子患者,杂合子也有出血并发症的风险。然而,获得性因子 XIII 缺乏症更为常见,初步研究表明,缺乏因子 XIII 是各种疾病的一个重要特征。在急性状态和严重出血时,建议使用因子 XIII 浓缩物进行替代治疗。检测方法的最新进展和未来的临床研究应有助于评估因子 XIII 的治疗潜力。